Published in final edited form as:

Biochemistry. 2011 August 16; 50(32): 6933–6941. doi:10.1021/bi2005202.

G protein-coupled receptor kinase 5 phosphorylation of Hip regulates internalization of the chemokine receptor CXCR4

Breann L. Barker and Jeffrey L. Benovic*

Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107

Abstract

Regulation of the magnitude, duration and localization of G protein-coupled receptor (GPCR) signaling responses is controlled by desensitization, internalization and down-regulation of the activated receptor. Desensitization is initiated by the phosphorylation of the activated receptor by GPCR kinases (GRKs) and the binding of the adaptor protein arrestin. In addition to phosphorylating activated GPCRs, GRKs have been shown to phosphorylate a variety of additional substrates. An *in vitro* screen for novel GRK substrates revealed Hsp70 interacting protein (Hip) as a substrate. GRK5, but not GRK2, bound to and stoichiometrically phosphorylated Hip *in vitro*. The primary binding domain of GRK5 was mapped to residues 303–319 on Hip, while the major site of phosphorylation was identified to be Ser-346. GRK5 also bound to and phosphorylated Hip on Ser-346 in cells. While Hip was previously implicated in chemokine receptor trafficking, we found that the phosphorylation of Ser-346 was required for proper agonist-induced internalization of the chemokine receptor CXCR4. Taken together, Hip has been identified as a novel substrate of GRK5 *in vitro* and in cells and phosphorylation of Hip by GRK5 plays a role in modulating CXCR4 internalization.

G protein-coupled receptors (GPCRs¹) elicit a variety of cellular responses via activation of downstream signaling pathways. Tight control of the magnitude, duration and location of these signaling responses is critical for homeostasis. The mechanisms regulating receptor signaling include desensitization, internalization and down-regulation. Desensitization, the process by which cells become unresponsive to repeated stimulation, is initiated by phosphorylation of the receptor by GPCR kinases (GRKs) and second messenger kinases, such as protein kinase A (PKA) and PKC. Phosphorylation of the receptor by GRKs recruits arrestins, further leading to receptor desensitization. Internalization, whereby receptors are removed from the cell surface, is largely mediated by clathrin-adaptor proteins, such as arrestins. Down-regulation, a decrease in the total number of receptors, may involve targeting GPCRs to the lysosome by ubiquitin-dependent interactions with components of the lysosomal sorting machinery (1–3).

GRKs are serine/threonine protein kinases that preferentially phosphorylate agonist-occupied GPCRs. The GRK family is composed of seven members, GRK1–7, and subdivided into three subclasses based on homology, GRK1 and 7, GRK2 and 3, and GRK4, 5, and 6 (4, 5). Although all of the GRKs have distinct regulatory mechanisms, all GRKs consist of an N-terminal domain that contains a regulator of G-protein signaling homology

*Address Correspondence to: Department of Biochemistry and Molecular Biology, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107. Tel: 215-503-4607; Fax: 215-503-5393; benovic@mail.jci.tju.edu.

¹The abbreviations used are: DMEM, Dulbecco's modified Eagle's Medium; GPCR, G protein-coupled receptor; GRK, GPCR kinase; GST, Glutathione S-Transferase; Hip, Heat Shock 70 interacting protein; PBS, phosphate buffered saline; PC, phosphatidylcholine; shRNA, short hairpin RNA; siRNA, short interfering RNA; TPR, Tetraco peptide repeat

domain, a central kinase domain that is related to AGC kinases, such as PKA and PKC, and a C-terminal domain that is the most variable (4, 5). The C-termini of GRK2 and 3 contain a pleckstrin homology domain that binds phospholipids and G $\beta\gamma$ subunits and mediates plasma membrane recruitment upon receptor activation (6–8), the C-termini of GRK4 and 6 are palmitoylated, which contributes to their plasma membrane localization (9–11) and the C-terminus of GRK5 directly binds lipids (12, 13).

Work examining GRK2 knockout mice and various cellular studies led to the search for non-receptor substrates of GRKs. Initial studies identified tubulin as the first non-receptor substrate of GRKs (14, 15). Subsequent studies identified Smoothed (16, 17), PDGF receptor (18), EGF receptor (18), synucleins (19), phosphoinositide 3-kinase (20), PDE γ (21), R-Smads (22), Ezrin (23), NF κ B1 p105 (24), p38 (25), downstream regulatory element antagonist modulator (DREAM) (26), histone deacetylase 5 (HDAC5) (27), arrestin2 (28) and p53 (29). The majority of these substrates were found to be substrates of GRK2 and were not found using a systematic approach.

In order to identify novel non-receptor substrates of GRK5, a bovine brain lysate was screened for GRK5 substrates using an *in vitro* kinase assay. One of the novel substrates was identified as Hsp70 interacting protein (Hip), which functions as a co-chaperone to other heat shock proteins, such as Hsp70 and Hsp90, to mediate protein folding, assembly of multi-protein complexes and transport of proteins within the cell. Here, we show that Hip is a novel non-receptor substrate and binding partner of GRK5 *in vitro* and in cells. GRK5 phosphorylates Hip primarily at Ser-346 and phosphorylation of this residue modulates the ability of Hip to mediate internalization of the chemokine receptor, CXCR4.

MATERIAL AND METHODS

Cell Culture and Transfections

HEK293 and HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. HEK293 cells ~70% confluent in 10-cm plates were transiently transfected with 600 pmol of siRNA using Lipofectamine2000 (Invitrogen) for 72 hr as per the manufacturer's instructions. HEK293 and HeLa cells were transiently transfected with 6 μ g of plasmid DNA using Fugene6 (Roche) for 48 hr. Cells stably expressing an shRNA against Hip were selected and maintained in DMEM containing 10% fetal bovine serum and 100 μ g/ml of hygromycin.

Hip wild type and domain deletion cDNAs were generously provided by Dr. Marc B. Cox from the University of Texas at El Paso in a pSPUTK vector. Hip was then subcloned into pTrcHisB vector using BglII and KpnI, into pGEX4T using SalI and EcoRI and into pcDNA3 using EcoRI and NotI. Point mutations were introduced by site-directed mutagenesis using QuikChange II Site-Directed Mutagenesis Kit (Stratagene) and confirmed using dideoxy sequencing.

siRNA oligos targeting GRK2, 3, 5 and 6 were synthesized by Dharmacon and were previously described (30). An shRNA vector targeting Hip was a generous gift from Dr. Marc B. Cox from the University of Texas at El Paso. The shRNA targeted the sequence 5'-ACCAGTGTACCTCTGACCT-3' which spans base pairs 1277–1299 in the 3' untranslated region of the Hip gene and was inserted into pSilencerTM hygro vector (Ambion).

Purification of His-tagged Hip Constructs

Hip expression was induced in BL21(DE3) cells at 30°C for 4 hr using 0.1 mM IPTG. Cells were collected by centrifugation, frozen at –80°C and thawed in buffer containing 100 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol and protease inhibitor tablets without EDTA (Roche).

The cell lysate was then homogenized, sonicated and centrifuged at 32,000×g. The supernatant was applied to a Ni-NTA Sepharose column. The column was washed and the bound proteins were eluted with a 20–500 mM gradient of imidazole. Peak fractions were pooled, concentrated and applied to a gel filtration column using a buffer containing 20 mM Tris-HCl, pH 8.0, 5 mM EDTA, 50 mM NaCl and 1 mM dithiothreitol. Peak fractions were again pooled, concentrated and frozen at –80°C. The purified protein was analyzed by SDS-PAGE and Coomassie staining and the concentration was determined using a Bradford assay.

In vitro Kinase Assay

GRK2 and GRK5 were purified as previously described (31, 32). Hip (100 nM) was incubated with 100 nM GRK5 or GRK2 in 10 mM Tris-HCl, pH 7.5, 2 mM EDTA, 7.5 mM MgCl₂, 100 μM ATP and 1–2 μCi of [γ -³²P] ATP for various times at 30°C while shaking. For assays including crude phosphatidylcholine (PC), PC was resuspended in buffer containing 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 50 mM NaCl and sonicated for 10 sec at room temperature. PC (0.1 mg/ml) was added to the reaction as indicated. Kinase assays were terminated by the addition of SDS sample buffer. Samples were separated by SDS-PAGE and the gels were dried onto filter paper and subjected to autoradiography. The amount of [³²P] phosphate incorporated was determined by scintillation counting of the excised protein bands.

Glutathione S-Transferase (GST) Pulldown Assays

GST Hip Wt and mutant proteins were expressed in BL21(DE3) cells. Cells were then lysed in buffer containing 20 mM Hepes, 0.02% Triton X-100, 100 mM NaCl, 10 mM EDTA and a protease inhibitor tablet (Roche) and centrifuged at 16,000×g. Soluble protein was incubated with Glutathione Sepharose beads followed by extensive washing of the beads. The purity of the proteins was assessed by Coomassie staining and protein concentrations were determined using a Bradford assay. GST Hip proteins (21 pmol) were incubated with 3 pmol of purified GRK2 or GRK5 in total volume of 500 μl of Buffer (20 mM Hepes, pH 7.2, 100 mM potassium acetate, and 0.1% Triton) at room temperature for 1.5 hr. Beads were washed extensively and bound protein was eluted by the addition of SDS sample buffer. Proteins were separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted for GRK5 using a GRK4–6 monoclonal antibody (Millipore). The amount of bound GRK5 was quantitated using an Odyssey scanner (Li-Cor Biotechnology).

Coimmunoprecipitations

Cells were washed with ice-cold phosphate buffered saline (PBS) and lysed in a buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 50 mM NaCl, 1% Triton X-100 and a protease inhibitor tablet (Roche). Equivalent amounts of cell lysates were immunoprecipitated with a polyclonal anti-HA antibody (Covance). Immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted with a monoclonal anti-GRK4–6 antibody (Millipore). Blots were then stripped and reprobed with a monoclonal anti-Hip antibody (Novus Biologics). Total cell lysates were probed with anti-Hip, anti-GRK4–6 and anti- α -tubulin (Sigma) antibodies. Immunoblots were incubated with SuperSignal Enhanced Chemiluminescent (Thermo Scientific) substrate, exposed to film and developed.

Hip Phosphorylation in HEK293 Cells

Cells were washed with ice-cold PBS 72 hr post-transfection and lysed in the same lysis buffer described above containing a PhosSTOP tablet (Roche). The HA tagged Hip was then immunoprecipitated from equivalent amounts of cell lysates using a monoclonal anti-HA

antibody (Covance). For experiments utilizing λ -phosphatase (λ -PPase) (New England Biolabs), immunoprecipitates were incubated with 800 U of λ -PPase for 30 min at 30°C in a buffer containing Mn^{2+} . For experiments requiring CXCR4 activation, cells were serum starved for 30 min and then stimulated with 50 nM CXCL12 for 15 min prior to lysis. Immunoprecipitates were then separated by SDS-PAGE, transferred to low-fluorescence PVDF membranes and stained with Pro-Q Diamond Stain (Invitrogen) according to the manufacturer's instructions. Phosphorylated Hip was visualized using a Typhoon Scanner (GE Healthcare) and quantified using ImageQuant 5.2 software (GE Healthcare). Membranes were then probed for total Hip using a polyclonal anti-Hip antibody (Cell Signaling).

CXCR4 Internalization Assay

Control or Hip shRNA HeLa cells were transfected with wild-type FLAG CXCR4 and pcDNA, Hip Wt, Hip-S346A or Hip-S346D plasmid as indicated and assayed 48 hr post-transfection. Serum starved cells were stimulated with 50 nM CXCL12 for 30 min at 37°C, washed with ice-cold PBS and fixed with 4% paraformaldehyde on ice. The amount of remaining cell surface CXCR4 was determined using a cell surface ELISA. Cells were incubated with M1 anti-FLAG antibody (Sigma), washed and incubated with a HRP conjugated horse anti-mouse secondary antibody (Vector Laboratories). After washing, cells were incubated with 1-step ABTS (Pierce). An aliquot was removed and the absorbance at 405 nm was determined.

Statistical Analysis

All statistics were performed using a Student's t-test.

RESULTS

Identification of Hip as a GRK5 substrate

To identify potential novel GRK substrates, a bovine brain lysate was screened for proteins that are phosphorylated by GRKs. A crude bovine brain lysate was initially resolved using Q sepharose chromatography and fractions were subjected to *in vitro* phosphorylation in the presence or absence of purified GRK2 or GRK5. This analysis identified an ~50 kDa protein that was phosphorylated in a GRK5 dependent manner. The fraction was further separated using size exclusion chromatography, which resulted in the identification of a single Coomassie stained band that was phosphorylated by GRK5. Mass spectral analysis of this band identified 20 unique peptides of which 13 were mapped to Hsp70 interacting protein (Hip) providing 13.6% sequence coverage (data not shown).

To confirm that Hip was a substrate of GRK5 *in vitro*, hexa-histidine tagged Hip was expressed in *E. coli*, purified using Ni^{2+} agarose and gel filtration chromatography (Fig. 1A) and subjected to *in vitro* phosphorylation by GRK2 and GRK5 (Fig. 1B). GRK5 phosphorylated Hip with a stoichiometry of ~0.5 mol of phosphate per mol of Hip, while GRK2 phosphorylated Hip to a significantly lesser extent (Fig. 1C). Since the *in vitro* phosphorylation of Hip by GRK5 was slow, modulators of GRK5 activity, including phosphatidylcholine (PC) and calmodulin, were tested for their ability to enhance phosphorylation of Hip. Addition of PC significantly enhanced the rate of phosphorylation and increased the stoichiometry to 1 mol of phosphate per mol of Hip (Fig. 1D). In contrast, the addition of calmodulin inhibited Hip phosphorylation (data not shown).

To determine if Hip binds to GRK5, we used GST-pulldowns and co-immunoprecipitations in cells. Hip was expressed as a GST fusion protein in *E. coli* and purified using glutathione beads. GST-Hip was able to bind to GRK5, but not GRK2, *in vitro* (Fig. 2A). To assess

binding of Hip to GRK5 in cells, HA-tagged Hip was expressed at a low level and utilized for immunoprecipitation since a good antibody to immunoprecipitate endogenous Hip was unavailable. Overexpressed GRK5 co-immunoprecipitated with HA-tagged Hip (Fig. 2B), demonstrating interaction between GRK5 and Hip in cells.

Identification of the GRK5 binding site on Hip

Hip can be divided into five domains: an N-terminal domain, a tetracoordinate repeat (TPR) domain, a highly charged region, a region enriched in glycine, methionine and proline (GGMP) and a C-terminal domain (Fig. 3A). The TPR domain and charged region of Hip bind to the ATPase domain of Hsp70, while the GGMP and C-terminal domains bind to the peptide binding domain of Hsp70 (33). Interestingly, previous studies have shown that Hip can bind to the chemokine receptors CXCR2 and CXCR4 in an agonist-dependent manner and that the TPR domain of Hip appears to be involved in the internalization of these receptors (34). To further define the site where GRK5 binds to Hip, we performed *in vitro* binding assays using various deletion mutants of GST-tagged Hip (Fig. 3A). The Hip Δ TPR domain protein did not express well in *E. coli* as a GST-fusion protein and therefore was not evaluated for binding to GRK5. The deletion of the N-terminal domain (Δ 1–99) and charged region (Δ charge) of Hip did not result in any significant change in binding to GRK5 (Fig. 3B & C). Binding of Hip to the GGMP deletion mutant (Δ GGMP) was reduced compared to wild type while binding to the C-terminal deletion (Δ 303–369) protein was almost completely lost (Fig. 3B & C). These data suggest that Hip primarily binds to regions within the C-terminal domain and may form weak interactions with the GGMP domain. To further define where the binding site was located, a series of C-terminal Hip truncation mutants were purified and tested for binding to purified GRK5. C-terminal deletions of 16, 33 or 50 amino acids had minimal effect on binding while deletion of 66 residues (Δ 303–369) effectively disrupted GRK5 binding (Fig. 3D & E). This suggests that binding is primarily occurring between residues 303 and 319, which contains the sequence GMPGMAGMPGLNEILS.

Identification of the GRK5 phosphorylation site in Hip

To identify the GRK5 phosphorylation site in Hip, the serial Hip deletion mutants described in Fig. 3A were subcloned into a pTrc vector, expressed as hexa-histidine tagged proteins and purified to near homogeneity (Fig. 4A). The purified proteins were then phosphorylated by GRK5 *in vitro*. While the Hip Δ charge and Δ GGMP proteins were phosphorylated to a level comparable to wild type, phosphorylation of the Δ 1–99 and Δ TPR proteins was enhanced almost 5-fold compared to wild type (Fig. 4B & C). The enhanced phosphorylation of these two forms of Hip suggests that the optimal conditions for phosphorylation of wildtype Hip by GRK5 are not achieved in the *in vitro* system being used. It seems likely that other factors, such as interacting partners of GRK5 or Hip, may be needed to activate GRK5 and/or promote a conformational change in Hip that is necessary for optimal phosphorylation to occur. These data also suggest that under the correct physiological conditions that there may be multiple sites of phosphorylation by GRK5. Interestingly, the Hip Δ 303–369 protein was poorly phosphorylated by GRK5 (Fig. 4B & C), suggesting that the primary site of phosphorylation is within this region.

We next attempted to identify the site of phosphorylation by mass spectrometry. Mass spectral analysis of peptides from a trypsin digestion of *in vitro* phosphorylated Hip was unable to detect any phosphorylated peptides, even when phosphopeptide enrichment was performed. However, it was noted that trypsin digestion of Hip resulted in a 7 kDa peptide that spans residues 273–347 (Fig. 5A). This fragment significantly overlaps with the C-terminal 303–369 region of Hip that contains the primary site of GRK5 phosphorylation (Fig. 4). To determine if phosphorylation of Hip was occurring within the 7 kDa trypsin

peptide of Hip, Hip was phosphorylated with radiolabeled ATP. The [^{32}P] phosphorylated Hip was then separated from GRK5 on SDS-PAGE, excised and digested with trypsin. The peptides that resulted from the trypsinization were then subjected to SDS-PAGE on a 20% polyacrylamide gel. Radioactively labeled bands were detected at 7 kDa as well as in the dye-front where most peptides from the Hip digestion would run (data not shown), suggesting that at least one site of phosphorylation was occurring within residues 273 and 347 and another site was found outside of this region. Taken together with the phosphorylation of the serial deletion mutants of Hip (Fig. 4), these data suggest that one of the sites of phosphorylation was within residues 303 and 347. Within this region there are no threonines and two serines, Ser-318 and Ser-346 (Fig. 5A). To test whether either of these residues is phosphorylated by GRK5, alanine mutations of the residues were generated and purified (Fig. 5B). GRK5 was able to phosphorylate the S318A mutant similar to wild type Hip, but was unable to phosphorylate the S346A mutant (Fig. 5C), suggesting that Ser-346 is a primary site of phosphorylation by GRK5.

GRK5 phosphorylates Ser-346 in Hip in HEK293 cells

Towards determining the ability of GRK5 to phosphorylate Hip in cells, we attempted to observe phosphorylation of Hip by examining a gel shift in SDS-PAGE. This strategy was unsuccessful at examining Hip phosphorylation *in vitro* or in cells. We were also unsuccessful generating site-specific phosphoantibodies targeting Ser-346. However, the phosphate specific dye, ProQ Diamond, was able to detect the phosphorylation of immunoprecipitated Hip in HEK293 cells (Fig. 6A). siRNA knockdown of the endogenous GRKs in HEK293 cells was used to determine which members of this kinase family were able to phosphorylate Hip in cells. Depletion of GRK5 resulted in an ~35% decrease in Hip phosphorylation, while depletion of GRK3 and GRK6 showed a 20–25% decrease in phosphorylation (Fig. 6B & C). These data demonstrate that GRK5 is able to phosphorylate Hip in cells, although it is evident that GRK3, GRK6 and possibly additional kinases also contribute to Hip phosphorylation. To determine if GRK5 phosphorylates Hip at Ser-346, the Hip-S346A mutant was expressed in cells treated with control or GRK5 siRNA. The Hip-S346A mutant consistently exhibited decreased phosphorylation compared to wild type Hip (Fig. 7). Furthermore, knockdown of GRK5 was not able to further decrease the extent of S346A phosphorylation (Fig. 7). Taken together, these data suggest that Hip is phosphorylated by GRK5 in cells. As staining of Hip with Pro-Q diamond is unable to distinguish between multiple sites of phosphorylation by different kinases, these data suggest that while Ser-346 is primarily phosphorylated by GRK5, additional sites phosphorylated by other kinases contribute to the global phosphorylation of Hip in cells observed with ProQ Diamond staining.

Phosphorylation of Ser-346 promotes internalization of CXCR4

Hip ΔTPR inhibits the internalization of CXCR4 when overexpressed (34) and is phosphorylated by GRK5 better than wild type Hip *in vitro* (Fig. 4). These data suggest that phosphorylation of Hip by GRK5 may modulate the ability of Hip to promote CXCR4 internalization. To examine the role of Hip Ser-346 phosphorylation in modulating CXCR4 internalization, the endogenous expression of Hip was knocked down using a shRNA directed against the 3' UTR of Hip. This resulted in an ~75% reduction in endogenous Hip levels (Fig. 8A). Hip wild type, S346A and S346D mutants along with wild type FLAG-CXCR4 were then expressed in the shRNA expressing cells (Fig. 8A). By rescuing the shRNA knock down of Hip with exogenous Hip, the effects of the point mutations were investigated without the complication of expression of the endogenous Hip. Upon stimulation of CXCR4 with its ligand, CXCL12, for 30 min in control cells, ~15% of Flag-tagged CXCR4 was internalized (Fig. 8B). The internalization of CXCR4 was almost completely inhibited in the Hip shRNA expressing cells, which was fully rescued by the

overexpression of wild type Hip. Furthermore, expression of the phosphomimetic S346D mutant, but not the S346A mutant, was able to rescue internalization of Hip in the shRNA expressing cells (Fig. 8B). These data suggest a novel role of GRK5 in modulating CXCR4 internalization by phosphorylating the non-receptor substrate Hip at Ser-346.

Towards understanding the role of CXCR4 activation in regulating phosphorylation of Ser-346 in Hip, HEK293 cells expressing CXCR4 and either wild type or S346A Hip were stimulated with CXCL12 and Hip phosphorylation was assessed using ProQ Diamond staining (Fig. 9A & B). Wild type Hip phosphorylation was decreased ~25% upon activation of CXCR4, while phosphorylation of the S346A mutant was not affected. Taken together, these data suggest that while the basal phosphorylation of Ser-346 is important for promoting internalization of activated CXCR4, receptor association results in dephosphorylation of Ser-346 and resets the system for another round of GRK5-mediated Hip phosphorylation.

DISCUSSION

Traditionally, GRKs phosphorylate activated GPCRs in order to desensitize the receptor and attenuate downstream signaling responses. Recent evidence has suggested that GRKs can phosphorylate non-GPCR substrates, such as tubulin (14, 15), ezrin (23), arrestin2 (28) and p53 (29), along with several others. The ability of GRKs to phosphorylate non-receptor substrates suggests that these proteins have many functional roles. Indeed, phosphorylation of ezrin by GRK2 promotes actin rearrangement and influences the internalization of the β_2 AR (23) while phosphorylation of arrestin2 by GRK5 inhibits G-protein independent ERK1/2 signaling downstream of the 5HT₄ receptor (28). These studies suggest that GRKs have many undiscovered roles in the signaling and trafficking of GPCRs and possibly in other non-GPCR related processes.

To attempt to discover novel functions of GRKs, a systematic screen for non-GPCR substrates of GRK5 was initiated. Hip was identified as a novel GRK5 substrate by screening a bovine brain lysate for substrates phosphorylated in a GRK-dependent manner. GRK5 was found to bind to Hip between residues 303 and 319 within the C-terminal portion of the protein and phosphorylate Ser-346 both *in vitro* and in cells. Phosphorylation of Ser-346 appeared to be required for agonist-induced internalization of CXCR4, a GPCR for the chemokine CXCL12. These data suggest a novel function of GRKs in modulating trafficking of a GPCR via phosphorylation of the non-receptor substrate Hip. Interestingly, GRK5 phosphorylation of Ser-346 does not appear to be the only phosphorylation event occurring on Hip and further investigation will likely reveal novel kinases and phosphorylation sites that regulate Hip function.

CXCR4 has been implicated in the progression of various disease states, including WHIM syndrome (35), human immunodeficiency virus-1 entry (36), and the progression of cancer (37). Thus, understanding the mechanisms controlling signaling and trafficking of this receptor can lead to novel therapeutics for the treatment of disease. Previous work examining the role of GRKs in signaling and trafficking of CXCR4 has failed to implicate a role for GRK5 in either of these processes. Overexpression of GRK5 in fibroblast cells had no effect on agonist-induced internalization of the receptor (38) and depletion of GRK5 by siRNA did not affect the ability of CXCR4 to stimulate calcium influx or activate ERK1/2 (30). Although GRK5 has not been implicated in signaling and trafficking of CXCR4 previously, this study suggests a novel role for GRK5 in CXCR4 trafficking that is independent of receptor phosphorylation and desensitization. There may also be functional redundancy between the GRK family members in modulating Hip phosphorylation. Although GRK5 appears to be the main kinase that phosphorylates Hip, knockdown of

GRK3 and GRK6 also had some effect on Hip phosphorylation in cells (Fig. 6) and both GRK3 and GRK6 have been implicated in CXCR4 signaling, trafficking and physiological responses (30, 38, 39). Although Hip binds to CXCR4 (34) and modulates internalization of the receptor by phosphorylation of Ser-346 (Fig. 8), the potential functional redundancy of GRKs in phosphorylating Hip (Fig. 6C) makes it unlikely that GRK5 alone regulates CXCR4 internalization through Hip. Taken together, these data suggest that GRKs play an essential role in CXCR4-mediated cellular responses through both canonical and non-canonical mechanisms.

Identification and characterization of novel non-receptor substrates of GRKs has led to the realization that GRKs play roles in GPCR trafficking other than the canonical phosphorylation and desensitization originally described. Phosphorylation of non-receptor substrates are likely to play roles in cellular processes that are not related to GPCR signaling, such as protein folding and maturation in the case of Hip phosphorylation by GRK5. Future work identifying non-receptor substrates of GRKs will likely reveal even more non-canonical roles for this family of kinases.

Acknowledgments

This work was supported by National Institutes of Health Grants R01 GM44944 and R01 CA129626.

Hip wild type and domain deletion cDNAs and an shRNA vector targeting Hip were generously provided by Dr. Marc B. Cox from the University of Texas at El Paso. We also thank Dr. Christina Pao and Ms. Michelle Kratz for providing purified GRK2 and GRK5.

References

1. Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. *Annu Rev Physiol.* 2007; 69:451–482. [PubMed: 17037978]
2. Marchese A, Chen C, Kim YM, Benovic JL. The ins and outs of G protein-coupled receptor trafficking. *Trends Biochem Sci.* 2003; 28:369–376. [PubMed: 12878004]
3. Drake MT, Shenoy SK, Lefkowitz RJ. Trafficking of G protein-coupled receptors. *Circ Res.* 2006; 99:570–582. [PubMed: 16973913]
4. Penn RB, Pronin AN, Benovic JL. Regulation of G protein-coupled receptor kinases. *Trends Cardiovasc Med.* 2000; 10:81–89. [PubMed: 11150735]
5. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. *Annu Rev Biochem.* 1998; 67:653–692. [PubMed: 9759500]
6. Carman CV, Barak LS, Chen C, Liu-Chen LY, Onorato JJ, Kennedy SP, Caron MG, Benovic JL. Mutational analysis of G $\beta\gamma$ and phospholipid interaction with G protein-coupled receptor kinase 2. *J Biol Chem.* 2000; 275:10443–10452. [PubMed: 10744734]
7. Onorato JJ, Gillis ME, Liu Y, Benovic JL, Ruoho AE. The beta-adrenergic receptor kinase (GRK2) is regulated by phospholipids. *J Biol Chem.* 1995; 270:21346–21353. [PubMed: 7673171]
8. Pitcher JA, Fredericks ZL, Stone WC, Premont RT, Stoffel RH, Koch WJ, Lefkowitz RJ. Phosphatidylinositol 4,5-bisphosphate (PIP₂)-enhanced G protein-coupled receptor kinase (GRK) activity. Location, structure, and regulation of the PIP₂ binding site distinguishes the GRK subfamilies. *J Biol Chem.* 1996; 271:24907–24913. [PubMed: 8798768]
9. Premont RT, Macrae AD, Stoffel RH, Chung N, Pitcher JA, Ambrose C, Inglese J, MacDonald ME, Lefkowitz RJ. Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. *J Biol Chem.* 1996; 271:6403–6410. [PubMed: 8626439]
10. Stoffel RH, Randall RR, Premont RT, Lefkowitz RJ, Inglese J. Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family. *J Biol Chem.* 1994; 269:27791–27794. [PubMed: 7961702]
11. Loudon RP, Benovic JL. Altered activity of palmitoylation-deficient and isoprenylated forms of the G protein-coupled receptor kinase GRK6. *J Biol Chem.* 1997; 272:27422–27427. [PubMed: 9341194]

12. Kunapuli P, Gurevich VV, Benovic JL. Phospholipid-stimulated autophosphorylation activates the G protein-coupled receptor kinase GRK5. *J Biol Chem.* 1994; 269:10209–10212. [PubMed: 8144599]
13. Thiyagarajan MM, Stracquatano RP, Pronin AN, Evanko DS, Benovic JL, Wedegaertner PB. A predicted amphipathic helix mediates plasma membrane localization of GRK5. *J Biol Chem.* 2004; 279:17989–17995. [PubMed: 14976207]
14. Carman CV, Som T, Kim CM, Benovic JL. Binding and phosphorylation of tubulin by G protein-coupled receptor kinases. *J Biol Chem.* 1998; 273:20308–20316. [PubMed: 9685381]
15. Pitcher JA, Hall RA, Daaka Y, Zhang J, Ferguson SS, Hester S, Miller S, Caron MG, Lefkowitz RJ, Barak LS. The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. *J Biol Chem.* 1998; 273:12316–12324. [PubMed: 9575184]
16. Chen W, Ren XR, Nelson CD, Barak LS, Chen JK, Beachy PA, de Sauvage F, Lefkowitz RJ. Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. *Science.* 2004; 306:2257–2260. [PubMed: 15618519]
17. Meloni AR, Fralish GB, Kelly P, Salahpour A, Chen JK, Wechsler-Reya RJ, Lefkowitz RJ, Caron MG. Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. *Mol Cell Biol.* 2006; 26:7550–7560. [PubMed: 16908539]
18. Freedman NJ, Kim LK, Murray JP, Exum ST, Brian L, Wu JH, Peppel K. Phosphorylation of the platelet-derived growth factor receptor-beta and epidermal growth factor receptor by G protein-coupled receptor kinase-2. Mechanisms for selectivity of desensitization. *J Biol Chem.* 2002; 277:48261–48269. [PubMed: 12381737]
19. Pronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. *J Biol Chem.* 2000; 275:26515–26522. [PubMed: 10852916]
20. Ruiz-Gomez A, Humrich J, Murga C, Quitterer U, Lohse MJ, Mayor F Jr. Phosphorylation of phosducin and phosducin-like protein by G protein-coupled receptor kinase 2. *J Biol Chem.* 2000; 275:29724–29730. [PubMed: 10884381]
21. Wan KF, Sami BS, Frame M, Tate R, Pyne NJ. The inhibitory gamma subunit of the type 6 retinal cyclic guanosine monophosphate phosphodiesterase is a novel intermediate regulating p42/p44 mitogen-activated protein kinase signaling in human embryonic kidney 293 cells. *J Biol Chem.* 2001; 276:37802–37808. [PubMed: 11502744]
22. Ho J, Cocolakis E, Dumas VM, Posner BI, Laporte SA, Lebrun JJ. The G protein-coupled receptor kinase-2 is a TGFbeta-inducible antagonist of TGFbeta signal transduction. *Embo J.* 2005; 24:3247–3258. [PubMed: 16121194]
23. Cant SH, Pitcher JA. G protein-coupled receptor kinase 2-mediated phosphorylation of ezrin is required for G protein-coupled receptor-dependent reorganization of the actin cytoskeleton. *Mol Biol Cell.* 2005; 16:3088–3099. [PubMed: 15843435]
24. Parameswaran N, Pao CS, Leonhard KS, Kang DS, Kratz M, Ley SC, Benovic JL. Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages. *J Biol Chem.* 2006; 281:34159–34170. [PubMed: 16980301]
25. Peregrin S, Jurado-Pueyo M, Campos PM, Sanz-Moreno V, Ruiz-Gomez A, Crespo P, Mayor F Jr, Murga C. Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK. *Curr Biol.* 2006; 16:2042–2047. [PubMed: 17055984]
26. Ruiz-Gomez A, Mellstrom B, Tornero D, Morato E, Savignac M, Holguin H, Aurrekoetxea K, Gonzalez P, Gonzalez-Garcia C, Cena V, Mayor F Jr, Naranjo JR. G protein-coupled receptor kinase 2-mediated phosphorylation of downstream regulatory element antagonist modulator regulates membrane trafficking of Kv4.2 potassium channel. *J Biol Chem.* 2007; 282:1205–1215. [PubMed: 17102134]
27. Martini JS, Raake P, Vinge LE, DeGeorge B Jr, Chuprun JK, Harris DM, Gao E, Eckhart AD, Pitcher JA, Koch WJ. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. *Proc Natl Acad Sci U S A.* 2008; 105:12457–12462. [PubMed: 18711143]
28. Barthet G, Carrat G, Cassier E, Barker B, Gaven F, Pillot M, Framery B, Pellissier LP, Augier J, Kang DS, Claeysen S, Reiter E, Baneres JL, Benovic JL, Marin P, Bockaert J, Dumuis A. Beta-

- arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT₄ receptor signalling. *Embo J*. 2009; 28:2706–2718. [PubMed: 19661922]
29. Chen X, Zhu H, Yuan M, Fu J, Zhou Y, Ma L. G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. *J Biol Chem*. 2010; 285:12823–12833. [PubMed: 20124405]
30. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. *J Biol Chem*. 2010; 285:7805–7817. [PubMed: 20048153]
31. Kim CM, Dion SB, Onorato JJ, Benovic JL. Expression and characterization of two beta-adrenergic receptor kinase isoforms using the baculovirus expression system. *Receptor*. 1993; 3:39–55. [PubMed: 8394172]
32. Kunapuli P, Onorato JJ, Hosey MM, Benovic JL. Expression, purification, and characterization of the G protein-coupled receptor kinase GRK5. *J Biol Chem*. 1994; 269:1099–1105. [PubMed: 8288567]
33. Prapapanich V, Chen S, Toran EJ, Rimerman RA, Smith DF. Mutational analysis of the hsp70-interacting protein Hip. *Mol Cell Biol*. 1996; 16:6200–6207. [PubMed: 8887650]
34. Fan GH, Yang W, Sai J, Richmond A. Hsc/Hsp70 interacting protein (hip) associates with CXCR2 and regulates the receptor signaling and trafficking. *J Biol Chem*. 2002; 277:6590–6597. [PubMed: 11751889]
35. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, Klotman ME, Diaz GA. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. *Nat Genet*. 2003; 34:70–74. [PubMed: 12692554]
36. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science*. 1996; 272:872–877. [PubMed: 8629022]
37. Zlotnik A. Involvement of chemokine receptors in organ-specific metastasis. *Contrib Microbiol*. 2006; 13:191–199. [PubMed: 16627966]
38. Balabanian K, Levoe A, Klemm L, Lagane B, Hermine O, Harriague J, Baleux F, Arenzana-Seisdedos F, Bachelier F. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. *J Clin Invest*. 2008; 118:1074–1084. [PubMed: 18274673]
39. Fong AM, Premont RT, Richardson RM, Yu YR, Lefkowitz RJ, Patel DD. Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. *Proc Natl Acad Sci U S A*. 2002; 99:7478–7483. [PubMed: 12032308]

Figure 1. *In vitro* phosphorylation of purified Hip by GRK5

(A) Hexa-histidine tagged Hip was expressed in *E. coli* and purified using Ni²⁺ agarose and size exclusion chromatography. One microgram of purified Hip was separated by SDS-PAGE and Coomassie stained. (B) 100 nM of purified GRK2 or GRK5 was incubated with 100 nM of purified Hip for various times at 30°C in a buffer containing radiolabeled ATP. Samples were separated by SDS-PAGE and subjected to autoradiography. (C) The radioactively labeled bands from B were excised and quantitated by scintillation counting to determine the stoichiometry of phosphorylation. Data represent the mean $\pm$ S.D. from six separate experiments. (D) Mixed micelles were generated by sonication of resuspended PC. The *in vitro* kinase assays were performed as in B & C in the presence or absence of 0.1 mg/ml PC vesicles. Data represent the mean $\pm$ S.D. from four separate experiments.

Figure 2. GRK5 binds to Hip

(A) GST and GST-Hip were expressed in *E. coli* and purified using glutathione beads (Coomassie stain). 21 pmol of purified GST or GST-Hip was then incubated with 3 pmol of purified GRK2 or GRK5 for 1.5 hr at room temperature with rocking. The beads were washed and the bound proteins were eluted with the addition of SDS sample buffer. The proteins were then separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted for GRK2 or GRK5. The experiment was performed nine times. (B) HEK293 cells were transiently transfected with pcDNA, HA-tagged Hip Wt and GRK5 as indicated. Cells were lysed 48 hr post-transfection and immunoprecipitated using a polyclonal anti-HA antibody. Immunoprecipitates were then immunoblotted for GRK5 and Hip. Cell lysates were immunoblotted for Hip, GRK4–6 and tubulin expression. The data shown are representative of three independent experiments.

Figure 3. GRK5 binding to Hip

(A) Hip is divided into five domains: the N-terminal domain (residues 1–99, white), three tetracoordinate repeat domains (residues 116–226, gray labeled TPR), a highly charged domain (residues 228–283, white labeled + – + –), a domain enriched in glycine, methionine and proline (residues 280–303, black labeled G), and a C-terminal domain (residues 303–369, dark grey). (B) GST tagged Hip domain deletions were expressed in *E. coli* and purified using glutathione beads (Coomassie stain). 21 pmol of GST or GST-Hip deletion mutants were incubated with 3 pmol of purified GRK5 for 1.5 hr at room temperature. The beads were then extensively washed and SDS sample buffer was added to elute the bound proteins. The proteins were separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with a monoclonal GRK4–6 antibody. (C) The western blot in B was quantitated using Odyssey software. The data (mean $\pm$ S.D., n=3) are from three separate experiments. (D) GST pull-downs were performed as described in B using serial truncation mutants of Hip. (E) The western blot in D was quantitated using Odyssey software. The data (mean $\pm$ S.D., n=3) are from three separate experiments.

Figure 4. GRK5 phosphorylates Hip between residues 303 and 369

(A) Hexa-histidine tagged Hip deletion mutants were expressed in *E. coli* and purified using Ni^{2+} agarose and gel filtration chromatography. One microgram of purified protein was separated by SDS-PAGE and Coomassie stained. (B) 100 nM of purified GRK5 was incubated with 100 nM of purified Hip deletion mutants for various times at 30°C in a buffer containing radiolabeled ATP. Samples were separated by SDS-PAGE and subjected to autoradiography. (C) The radioactively labeled bands from B were excised and quantitated by scintillation counting to determine the stoichiometry of phosphorylation. Data represent the mean $\pm$ S.D. from five separate experiments.

Figure 5. Hip S346A mutant is not phosphorylated by GRK5

(A) The amino acid sequence of Hip between residues 273 and 369 is shown. The underlined portion highlights the residues in the Hip Δ 303–369 construct that are deleted. The arrows depict the sites of cleavage by trypsin that result in a 7 kDa fragment. Ser-318 and Ser-346 are in bold. (B) Hexa-histidine tagged Hip wild type, S318A and S346A mutants were expressed in *E. coli* and purified using Ni⁺ agarose and gel filtration chromatography. One microgram of purified protein was separated by SDS-PAGE and Coomassie stained. (C) 100 nM of purified GRK5 was incubated with 100 nM of purified Hip point mutants for various times at 30°C in a buffer containing radiolabeled ATP. Samples were separated by SDS-PAGE and subjected to autoradiography.

Figure 6. GRK5 phosphorylates Hip in cells

(A) HEK293 cells were transfected with pcDNA3 or HA Hip Wt. 48 hr post-transfection, cells were lysed and immunoprecipitated with a monoclonal anti-HA antibody. The immunoprecipitates were then subjected to dephosphorylation by λ -phosphatase for 30 min at 30°C. The immunoprecipitates were separated by SDS-PAGE, transferred to low-fluorescence PVDF membrane and stained with Pro-Q Diamond Stain. The stain was visualized using a Typhoon scanner. The PVDF membrane was then immunoblotted for Hip. (B) HEK293 cells were transfected with control (ctrl) or GRK specific siRNA and HA-Hip Wt in pcDNA3. Seventy two hours post-transfection the samples were prepared as described in A without λ -phosphatase treatment. Equivalent amounts of cell lysates were probed for GRK expression. (C) The amount of Pro-Q Diamond stain was quantitated using ImageQuant 5.2 software and was normalized to the amount of staining in the control siRNA treated samples. The data shown are the mean $\pm$ S.D. (* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$) from four separate experiments.

Figure 7. GRK5 phosphorylates Hip at Ser-346

(A) HEK293 cells were transfected with control (ctrl) or GRK specific siRNA and HA-Hip Wt or S346A in pcDNA3. Seventy two hr post-transfection, cells were lysed and immunoprecipitated with a monoclonal anti-HA antibody. The immunoprecipitates were separated by SDS-PAGE, transferred to low-fluorescence PVDF membrane and stained with Pro-Q Diamond Stain. The stain was visualized using a Typhoon scanner. The PVDF membrane was then immunoblotted for Hip. Equivalent amounts of cell lysates were probed for GRK5 expression. (B) The amount of Pro-Q Diamond stain was quantitated using ImageQuant 5.2 software and was normalized to the amount of staining in the control siRNA treated samples. The data shown are the mean $\pm$ S.D. (** $p \leq 0.01$, *** $p \leq 0.001$) from four separate experiments.

Figure 8. Hip Ser-346 mediates internalization of CXCR4

(A) Control (Ctrl) or Hip shRNA expressing HeLa cells were transiently transfected with FLAG-CXCR4 Wt and pcDNA3-Hip Wt, S346A or S346D. Equivalent amounts of cell lysate were separated by SDS-PAGE, transferred to nitrocellulose and probed for Hip expression. The membrane was stripped and probed for tubulin as a loading control. (B) Cells transfected as in A were serum starved and stimulated with 50 nM CXCL12 for 30 min. The cells were then fixed with 4% PFA and the remaining amount of surface CXCR4 was determined by cell surface ELISA. The data (mean $\pm$ S.D., $n=3$, ** $p \leq 0.01$, *** $p \leq 0.001$) are from five separate experiments and are expressed as the fraction of cell surface expression relative to the 0 min untreated control sample.

Figure 9. CXCR4 activation promotes dephosphorylation of Hip

(A) HEK293 cells were transfected with Flag-tagged CXCR4 and HA-tagged Wt or S346A mutant Hip. Forty eight hr post-transfection, cells were stimulated with 50 nM CXCL12 for 15 min, lysed and immunoprecipitated with a monoclonal anti-HA antibody. The immunoprecipitates were separated by SDS-PAGE, transferred to low-fluorescence PVDF membrane and stained with Pro-Q Diamond Stain. The stain was visualized using a Typhoon scanner. The PVDF membrane was then immunoblotted for Hip. (B) The amount of Pro-Q Diamond stain was quantitated using ImageQuant 5.2 software and was normalized to the amount of staining in the control siRNA treated samples. The data shown are the mean $\pm$ S.D. (* $p \leq 0.05$) from three separate experiments.